To print: Select File and then Print from your browser's menu

Title: Two-Year Z-FAST Trial Shows Zoledronic Acid Prevents Bone Loss in Breast Cancer Patients Taking Letrozole: Presented at SABCS

"Two-Year Z-FAST Trial Shows Zoledronic Acid Prevents Bone Loss in Breast Cancer Patients Taking Letrozole: Presented at SABCS"

By Charlene Laino SAN ANTONIO, TX -- December 18, 2006 -- Concurrent administration of the third-generation bisphosphonate zoledronic acid (Zometa) appears to prevent the bone loss often seen among early stage breast cancer patients on aromatase inhibitor therapy, researchers reported here at the 29[^th Annual San Antonio Breast Cancer Symposium (SABCS).

Two-year interim results from the Zometa-Femara Adjuvant Synergy Trial (Z-FAST) indicate that patients who were assigned to intravenous treatment with zoledronic acid 4 mg every 6 months along with 2.5 mg letrozole daily had improvements in bone density measures at key sites.

"At 24 months, upfront zoledronic acid increased lumbar spin bone mineral density 5.9% and total hip bone mineral density by 4.7% compared with patients who were on a delayed start of bisphosphonate therapy," said presenter Adam Brufsky, MD, assistant professor of medicine, Magee-Women's Hospital, University of Pittsburgh Medical Center/University of Pittsburgh Cancer Institute Breast Cancer Program, Pittsburgh, Pennsylvania.

In the Z-FAST study, 301 patients with early stage breast cancer were randomly assigned to receive zoledronic acid at the same time as they initiated treatment with letrozole. A second group of 301 patients were assigned to initiate letrozole alone, and were given zoledronic acid only if they had a marked decreased in bone mineral density as detected in imaging studies, if they had a symptomatic fracture or if they had an asymptomatic fracture by 36 months.

During the first 2 years of therapy, 12.7% of patients in the delayed cohort initiated zoledronic acid, Dr. Brufsky reported in a poster presentation on December 16^th.

At 24 months, the bone mineral density in the lumbar spine had increased by 3% among patients who initiated zoledronic acid at the same time as letrozole; those in the delayed treatment cohort experienced a 2.9% loss in bone mineral density at time point. That 5.9% overall difference reached statistical significance at the P < .0001, he said.

Bone mineral density in the total hip increased by 1.5% at 24 months among patients who initiated therapy with zoledronic acid at the same time as letrozole, while those in the delayed treatment cohort experienced a 3.2% loss at this time point. That 4.7% overall difference reached statistical significance at the P < .001, Dr. Brufsky said.

Clinical fractures occurred in 4.3% of the upfront bisphosphonate treatment group compared with 4% of the patients receiving delayed treatment, a nonsignificant difference, Dr. Brufsky said. "An analysis of fracture rates at 36 months is planned," he said.

[Presentation title: Twenty-Four Month Follow-Up of the Effect Of Zoledronic Acid (ZA) on Aromatase Inhibitor Associated Bone Loss (AIBL) in Postmenopausal Women (PMW) With Early Breast Cancer (BCa) Receiving Adjuvant Letrozole (LET). Abstract 5060]

Copyright © 2009 P\S\L Consulting Group Inc. All rights reserved. Republication or redistribution of P\S\L content is expressly prohibited without the prior written consent of P\S\L. P\S\L shall not be liable for any errors, omissions or delays in this content or any other content on its sites, newsletters or other publications, nor for any decisions or actions taken in reliance on such content.